Cancer Research AACR Conference on Molecular Diagnostics - 2008 Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 2587-2592, June 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryu, D.-Y.
Right arrow Articles by Snyderwine, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryu, D.-Y.
Right arrow Articles by Snyderwine, E. G.
[Cancer Research 59, 2587-2592, June 1, 1999]
© 1999 American Association for Cancer Research

Carcinogenesis

In Vivo Mutagenicity and Hepatocarcinogenicity of 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in Bitransgenic c-myc/{lambda}lacZ Mice

Doug-Young Ryu, Valerie S. W. Pratt, Cindy D. Davis1, Herman A. J. Schut and Elizabeth G. Snyderwine2

Chemical Carcinogenesis Section, Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892 [D-Y. R., V. S. W. P., C. D. D., E. G. S.] and Department of Pathology, Medical College of Ohio, Toledo, Ohio 43614 [H. A. J. S.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) is a mutagenic and carcinogenic heterocyclic amine found in cooked meat. Hepatic DNA adduct formation, in vivo mutagenicity, and hepatocarcinogenicity of MeIQx were examined in mice harboring the lacZ mutation reporter gene (Muta mice) and bitransgenic mice overexpressing the c-myc oncogene. C57Bl/{lambda}lacZ and bitransgenic c-myc (albumin promoter)/{lambda}lacZ mice were bred and weaned onto an American Institute of Nutrition-76-based diet containing 0.06% (w/w) MeIQx or onto control diet. After 30 weeks on diet, only male bitransgenic mice on MeIQx developed hepatocellular carcinoma (100% incidence). By 40 weeks, hepatic tumor incidence was 100%/75% (17%/0%) and 44%/17% (0%/0%) in male c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ mice who were given MeIQx (or control) diet, respectively, supporting a synergism between MeIQx and c-myc overexpression in hepatocarcinogenesis. At either time point, mutant frequency in the lacZ gene was at least 40-fold higher in MeIQx-treated mice than in control mice of either strain. These findings suggest that MeIQx-induced hepatocarcinogenesis is associated with MeIQx-induced mutations. Elevated mutant frequency in MeIQx-treated mice also occurred concomitant with the formation of MeIQx-guanine adducts, as detected by the 32P-postlabeling assay. Irrespective of strain or diet, sequence analysis of the lacZ mutants from male mouse liver showed that the principal sequence alterations were base substitutions at guanine bases. Adenine mutations, however, were detected only in animals on control diet. MeIQx-fed mice harboring the c-myc oncogene showed a 1.4–2.6-fold higher mutant frequency in the lacZ gene than mice not carrying the transgene. Although there was a trend toward higher adduct levels in c-myc mice, MeIQx-DNA adduct levels were not significantly different between c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ mice after 30 weeks on diet. Thus, it seemed that factors in addition to MeIQx-DNA adduct levels, such as the enhanced rate of proliferation associated with c-myc overexpression, may have accounted for a higher mutant frequency in c-myc mice. In the control diet groups, the lacZ mutant frequency was significantly higher in c-myc/{lambda}lacZ mice than in C57Bl/{lambda}lacZ mice. The findings are consistent with the notion that c-myc overexpression is associated with an increase in mutagenesis. The mechanism for the synergistic effects of c-myc overexpression on MeIQx hepatocarcinogenicity seems to involve an enhanced expression of MeIQx-induced mutations.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
MeIQx3 is a member of a family of mutagenic/carcinogenic HCAs found in cooked meats, including beef, chicken, and fish. MeIQx is currently recognized as the second most prevalent of the HCAs in the human diet (1) . In rodent carcinogenicity bioassays, MeIQx has been shown to be a strong liver carcinogen. In a previous study, the incidence of hepatic cancer in CDF1 mice exposed to 0.06% MeIQx in the diet for 84 weeks was 43% and 91% in males and females, respectively (2) .

MeIQx is a procarcinogen that requires metabolic activation to reactive ester derivatives to form DNA adducts, induce mutations, and initiate the process of carcinogenesis. In experimental animals (including rats, mice, and monkeys) who were fed MeIQx (3, 4, 5, 6) , MeIQx has been shown to form adducts at guanine nucleotides. Studies to determine the structures of MeIQx-DNA adducts reveal that the electrophilic metabolite of MeIQx reacts predominantly at the C8 and N2 positions of guanine, forming N2-(deoxyguanosin-8-yl)-MeIQx and 5-(deoxyguanosin-N2-yl)-MeIQx, respectively (5) . N2-(deoxyguanosin-8-yl)-MeIQx is the major adduct of MeIQx found in liver and other tissues of animals who were given MeIQx (3 , 4) .

MeIQx is known to be a potent mutagen in several in vitro assay systems, including the Ames Salmonella mutagenicity assay, and in the lacZ gene of Escherichia coli (7, 8, 9, 10) . MeIQx has also been shown to be genotoxic in vivo, as assessed by an animal-mediated microbial assay (11) , and in the lacZ gene of the Muta mice (12) . As with other HCAs (13) , in vitro mutagenicity studies support that MeIQx-DNA adducts play a role in the induction of specific genetic mutations (10) .

In the paradigm of the multistep model of carcinogenesis, the accumulation of multiple genetic alterations in critical genes is essential for the development of cancer. Deregulation of the c-myc gene by overexpression or amplification is one alteration that has been implicated in the development of hepatocellular carcinoma in both experimental models and humans (14) . c-Myc is a proto-oncogene involved in the regulation of DNA synthesis, differentiation, apoptosis, and cell cycle progression. Deregulation of c-myc can lead to a loss of cell cycle control, improper initiation of DNA synthesis, and genetic instability (14, 15, 16) . Recent studies in a c-myc transgenic mouse model have shown, however, that hepatic overexpression of c-myc leads to a low incidence of hepatocellular carcinoma after a long latency period (17 , 18) . Additional cooperating genetic alterations seem to be essential for hepatocarcinogenesis under conditions of c-myc deregulation (19) .

The central role of c-myc in cell cycle regulation and the requirement for multiple genetic alterations for hepatocarcinogenesis raise the question of whether the sensitivity to a chemical mutagen and hepatocarcinogen, such as MeIQx, is affected by overexpression of the c-myc oncogene. In a previous study, this laboratory described the use of a bitransgenic mouse harboring both the c-myc gene and the lacZ mutational reporter gene (12) . After an acute exposure, the in vivo mutagenicity of MeIQx and other HCAs was shown to be higher in c-myc/{lambda}lacZ bitransgenic mice than in control (C57Bl/{lambda}lacZ) mice. This study suggested the possibility of an interaction between the specific HCAs and the overexpressed c-myc gene. In the current study, we evaluate the roles of MeIQx-induced DNA adducts and mutagenesis in hepatocarcinogenesis, address whether c-myc overexpression modulates the mutagenicity of MeIQx, and examine if hepatic overexpression of c-myc alters the susceptibility to MeIQx hepatocarcinogenesis.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Chemicals.
MeIQx was purchased from Toronto Research Chemicals (North York, Ontario, Canada). AIN-76 diet was purchased from Harlan Teklad (Madison, WI). P-gal was purchased from Sigma Chemical Co. (St. Louis, MO). RNAce-It RNase mixture and Giga-Pack II were obtained from Stratagene (La Jolla, CA). The LacZ- galE- E. coli C strain with overexpressed galT and galK genes was a generous gift from Dr. Jan Vijg (Harvard Medical School, Boston, MA).

Animals and Treatment.
The MutaTM mouse [BALB/c x DBA/2 (CD2F1)] carrying the {lambda}lacZ transgene was purchased from Hazleton Research Products (Denver, PA). Female c-myc transgenic mice (C57Bl/6J x CBA/J) were a generous gift from Dr. S. S. Thorgeirsson (18) . C57Bl/{lambda}lacZ and c-myc/{lambda}lacZ mice were generated by breeding male Muta mice with female C57Bl/6J and c-myc transgenic mice. F1 mice were weaned onto AIN-76 diet containing 0.06% (w/w) MeIQx or AIN-76 (control) diet. Food and water were provided ad libitum throughout the study. Animal housing and care were in accordance with NIH guidelines.

Collection of Tissue Samples and Histology.
Mice were euthanized after 30 and 40 weeks on diet by cervical dislocation and autopsied. Livers were examined macroscopically for the appearance of tumor. Portions of liver and liver tumors were fixed in 10% formalin or promptly frozen in liquid nitrogen and stored at -80°C until DNA isolation. All fixed tissues were embedded in paraffin, and sections were stained with H&E. Sections of nontumorous liver and grossly visible tumors were examined, and the latter diagnosed as hepatocellular adenomas or carcinomas (20) .

32P-Postlabeling Analysis.
For 32P-postlabeling analysis, genomic DNA was isolated from frozen tissue essentially by the method described previously (21) . The analysis of MeIQx adducts in genomic DNA was performed by 32P-postlabeling analysis as before (3 , 4) , using the intensification (ATP-deficient) method (22) . This method resolves [32P]ATP-labeled bisphosphonucleotide adducts on polyethyleneimine-cellulose thin layer sheets as fingerprints after autoradiography.

Genomic DNA Extraction for lacZ Mutant Detection.
High molecular weight DNA was isolated from frozen mouse liver and tumor tissues according to the protocol described earlier (23) . Briefly, tissues were disaggregated and homogenized in dounce buffer [14 mM sodium phosphate (pH 8.0), 137 mM NaCl, 3 mM KCl, and 10 mM NaEDTA) containing 1/50 volume of RNAce-It RNase mixture. An equal volume of lysis buffer [2 mg/ml proteinase K, 2% SDS, and 0.1 M NaEDTA (pH 7.5)] was added. After a 3-h incubation at 50°C, the DNA was sequentially extracted with phenol/chloroform. The DNA was ethanol-precipitated, spooled onto a hooked glass Pasteur pipette, and then dissolved in 10 mM Tris buffer (pH 8.0) at 37°C to a concentration of 1–3 mg/ml.

Determination of Mutant lacZ Frequency.
To determine the frequency of mutations in the lacZ transgene in liver of mice, {lambda}gt10 DNA was rescued from genomic DNA by packaging into {lambda} phage using Giga-Pack II packaging extract (23) . Each packaging reaction was adsorbed to E. coli C at log phase growth. The reactions were then plated with and without P-gal. The number of plaques were counted after overnight incubation at 37°C. The lacZ - mutant frequency was determined as the ratio of lacZ - mutant plaques obtained in the presence of P-gal to the number of plaques recovered on the titer plates (23 , 24) . From each mouse-liver DNA sample, a minimum of 300,000 total plaques were scored on the titer plates.

Sequencing of Mutant lacZ.
LacZ mutants were sequenced as described previously (23) . Briefly, mutant plaques were picked randomly from plates and expanded in liquid culture before DNA isolation. Regions of the lacZ gene were amplified by PCRs and sequenced using the previously reported sequencing primers (23) . Sequencing reactions were performed using a DNA sequencing kit for dye terminator cycle reactions (Perkin-Elmer Corp., Foster City, CA). Automated sequencing was carried out on an ABI Prism 377 DNA Sequencer (Perkin-Elmer Corp.).

Statistical Analysis.
The data were analyzed by both two-way ANOVA (mouse strain and carcinogen treatment) and Student’s t tests using the computer program Prizm (GraphPad Software Incorporated, San Diego, CA).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
DNA Adduct Analysis.
32P-postlabeling analysis was used to measure MeIQx-DNA adduct levels in hepatic DNA from c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ strains of mice who received the MeIQx diet for 30 weeks. Three principle adduct spots, identical to those identified previously as guanine nucleotide adducts of MeIQx (4) , were detected in DNA from both strains. The profile of MeIQx-DNA adducts was also identical to that reported previously in c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ strains of mice who were given multiple doses of MeIQx (12) . No qualitative differences in MeIQx-DNA adduct formation was noted among the various treatment groups (data not shown). The major adduct comprising at least 50% of total adduct levels coincided chromatographically with the 3', 5' bisphosphate of N2-(deoxyguanosin-8-yl)-MeIQx, the C8-guanine adduct of MeIQx. For each gender, total MeIQx-DNA adduct levels were not statistically different between c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ mice, although there did seem to be a trend for slightly higher adduct levels in mice harboring the c-myc transgene (Fig. 1)Citation . Irrespective of mouse strain, MeIQx-DNA adduct levels were significantly higher in the females than in the males (P < 0.05, two-factor ANOVA). No MeIQx-DNA adducts were detected in animals on control diet.



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1. MeIQx-DNA adduct levels in the liver of C57Bl/{lambda}lacZ and c-myc/{lambda}lacZ mice who were given 0.06% (w/w) MeIQx containing diet for 30 weeks are shown. DNA adduct levels were determined by the 32P-postlabeling assay, as described in "Materials and Methods." Values are mean ± SE (n = 3). No adducts were detected in animals on control diet (data not shown). RAL, relative adduct labeling.

 
Mutant Frequency.
The mutant frequency in the lacZ gene of hepatic DNA was measured in c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ mice on MeIQx or control diet for 30 and 40 weeks (Fig. 2)Citation . The dietary MeIQx exposure had a striking effect on mutant frequency in the lacZ gene in both c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ mice. In both strains and at both time points, MeIQx-fed mice showed at least a 40-fold higher lacZ mutant frequency than mice on control diet (Fig. 2Citation , compare A with B and C with D). The presence of the c-myc transgene also affected mutant frequency of the lacZ transgene in both control and MeIQx treatment groups. In the MeIQx treatment groups, mutant frequency was 1.4–2.6-fold higher in mice harboring the c-myc transgene than that in the control strain (C57Bl/{lambda}lacZ; Fig. 2, B and DCitation ). This difference was statistically significant in males after 30 weeks on diet and in both males and females after 40 weeks on MeIQx diet (Fig. 2DCitation , compare c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ strains; Student’s t test, P < 0.05). In mice on control diet, the mutant frequency in the lacZ gene was 1.4–2.7-fold higher in mice that carried the c-myc transgene than in the control strain. The differences between the c-myc/{lambda}lacZ and C57Bl/{lambda}lacZ strains was statistically higher in female mice after 30 weeks on control diet and in both male and female mice after 40 weeks on control diet (Student’s t test, P < 0.05). Gender differences in lacZ mutant frequencies were also apparent among the animal groups. Within a treatment group, females showed statistically higher mutant frequencies than the respective males (Student’s t test, P < 0.05).



View larger version (33K):
[in this window]
[in a new window]
  		Fig. 2. LacZ gene mutant frequency in the liver of C57Bl/{lambda}lacZ and c-myc/{lambda}lacZ mice of both sexes who were given 0.06% MeIQx or control diet for 30 (A and B) and 40 (C and D) weeks is shown. Values are mean ± SE (n = 3). {square}, C57Bl/{lambda}lacZ; {blacksquare}, c-myc/{lambda}lacZ; An asterisk represents that lacZ gene mutant frequency in C57Bl/{lambda}lacZ and c-myc/{lambda}lacZ mice is significantly different (Student’s t test, P < 0.05). PFU, plaque-forming units.

 
Hepatic Tumor Incidence.
Hepatic tumor incidence was recorded after 30 and 40 weeks of feeding MeIQx or control diet (Fig. 3, A and B)Citation . After 30 weeks on diet, tumors were detected only in the c-myc/{lambda}lacZ male mice who were fed MeIQx (Fig. 3A)Citation . All of the four c-myc/{lambda}lacZ mice on MeIQx diet examined at this time point had developed several grossly visible tumor masses that were classified histologically as hepatocellular carcinomas. Grossly visible hepatic tumors were not detected in the other groups of male or female mice after 30 weeks. Microscopic changes, including the development of hepatic foci and adenomatous changes, were detected in two of four female c-myc/{lambda}lacZ mice who were fed MeIQx. Thus, at the 30-week time point, whereas neither MeIQx nor c-myc overexpression alone was sufficient to induce hepatocellular carcinomas, the combination of MeIQx treatment and c-myc overexpression was highly effective in inducing hepatocellular carcinomas in male mice.



View larger version (23K):
[in this window]
[in a new window]
  		Fig. 3. Incidence of grossly visible liver tumors in C57Bl/{lambda}lacZ and c-myc/{lambda}lacZ mice who were given 0.06% MeIQx containing diet for 30 (A) and 40 (B) weeks is shown. Values are the percentage of tumor-bearing mice out of n = 3–4 and n = 10–13 for 30 and 40 weeks, respectively. Tumors were classified as hepatocellular carcinomas. M, male; F, female.

 
After 40 weeks on diet, all of the groups of mice receiving MeIQx developed grossly visible hepatic tumors; however, strain and sex differences in tumor incidence were still observed (Fig. 3B)Citation . The highest incidence of tumors at 40 weeks was observed in the male c-myc/{lambda}lacZ mice who were given MeIQx. At this time point, hepatocellular carcinoma development involved much of the liver. Grossly visible isolated hepatic tumors, identified as hepatocellular carcinomas, were also seen in 80% of female c-myc/{lambda}lacZ mice on the MeIQx diet. Hepatocellular carcinomas were also observed in 44% and 17% of male and female C57Bl/{lambda}lacZ mice on MeIQx diet for 40 weeks, respectively. Approximately 17% of male c-myc/{lambda}lacZ mice on control diet developed grossly visible tumors after 40 weeks. The lacZ mutant frequency was also analyzed in hepatocellular carcinomas from MeIQx-treated mice after 40 weeks. There were no significant differences between the mutant frequencies (mean ± SE, n) in hepatocellular carcinomas and normal tissue from C57Bl/{lambda}lacZ males (1911 ± 337, 3 versus 2433 ± 297, 3), c-myc/{lambda}lacZ males (5192 ± 907, 3 versus 4954 ± 335, 3), or c-myc/{lambda}lacZ females (8358 ± 1505, 3 versus 7136 ± 659, 3). Tumors from the other groups did not provide sufficient tissue for analysis.

LacZ Sequence Analysis.
Sequence analysis of the lacZ gene mutants from liver of male mice was carried out to assess the types of mutations induced in the four different groups of mice: C57Bl/{lambda}lacZ on control or MeIQx diet and c-myc/{lambda}lacZ mice on control or MeIQx diet (Table 1)Citation . Irrespective of the animal strain or MeIQx treatment, the principal sequence alteration observed in the lacZ gene was a single base substitution. The frequency of CpG mutations varied with treatment groups and mouse strains (Table 1)Citation . In all four groups, the majority of all single-base mutations were at G:C bp, which consisted of G:C to T:A transversions, G:C to A:T transitions, and G:C to C:G transversions. There was no apparent strand bias in the occurrence of base substitution mutations. In either strain, adenine mutations were observed only when mice were on the control diet.


View this table:
[in this window]
[in a new window]
  		Table 1 Representative types of sequence alterations found in the lacZ gene of male transgenic mice

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
To address the role of multiple factors in MeIQx hepatocarcinogenesis, MeIQx-DNA adduct formation, in vivo mutagenicity, and carcinogenicity were examined in mice carrying the lacZ mutational reporter gene and an overexpressed c-myc oncogene. It is generally recognized that HCA-DNA adduct formation plays a role in HCA carcinogenesis. In the current study, MeIQx-DNA adduct formation was associated with elevated mutant frequency in the liver of mice. Irrespective of mouse strain, the mutant frequency in mice on the MeIQx diet was over 40-fold higher than in control mice, and, accordingly, MeIQx-DNA adducts were detected only in MeIQx-treated mice. Comparison between male and female mice also illustrate an association between MeIQx-DNA adduct levels and in vivo mutagenicity. In either strain of mice, MeIQx-DNA adduct levels were 2-fold higher in female mice than in male mice (Fig. 1)Citation . In accordance with higher MeIQx-DNA adduct levels, the mutant frequency in the lacZ reporter gene was 1.4–2.6-fold higher in female mice than in male mice (Fig. 2)Citation . The difference in adduct levels between male and female mice is likely to be associated with a higher capacity for metabolic activation in the females (25) .

In a previous study, we measured MeIQx-DNA adduct levels and mutant frequency in the lacZ gene in the liver of mice who were given 10 oral doses of MeIQx (12) . Comparison with the current data shows that the level of MeIQx-DNA adducts detected in liver after a 30-week dietary exposure to MeIQx are, on average, 2-fold higher than the levels found after the 10-dose regimen. Interestingly, mutant frequency in the lacZ gene was at least 15–20-fold higher after a 30-week exposure than after a 10-day exposure, despite the mere doubling in MeIQx-DNA adduct levels. These findings suggest that the duration of exposure to MeIQx or the persistence of MeIQx-DNA adducts is a more important determinant of in vivo mutagenesis than is the total adduct level. It seems likely that the increase in mutagenic response over an extended exposure to MeIQx is the result of a greater period of time for DNA adduct formation and the fixation of mutations. The data also suggest that DNA damaging mutations accumulate with chronic exposure to MeIQx.

The mutation spectra found in the lacZ gene of MeIQx-treated mice is also consistent with the involvement of MeIQx-DNA adducts in mutagenesis in vivo. In accordance with the formation of guanine adducts, all of the base substitution mutations observed in MeIQx-treated mice, irrespective of strain, occurred at the guanine base. The contribution of the different MeIQx-DNA adducts, such as the C8- guanine adduct, N2-guanine adduct, or the role of oxidative base damage, including 8-oxo-dG formation by MeIQx in the mutation spectra of MeIQx, is not yet known. In a previous study, Solomon et al. (10) showed that base substitution mutations associated with MeIQx-DNA adducts in the lacZ gene of E. coli in vitro include primarily G to T transversions, followed by G to A transition mutations. Both of these types of mutations were also observed in MeIQx-treated mice, although in C57Bl/{lambda}lacZ mice, G to A transition mutations were more common than G to T transversions. It is noteworthy, however, that the percentage of guanine base substitution mutations in mice on control diet was similar to that observed in mice on the MeIQx diet. Adenine mutations, however, were observed only in mice (of either strain) on control diet, and these mutations have been shown to occur spontaneously in the lacZ gene of the Muta mice (26) . Interestingly, c-myc overexpression seems to alter the percentage of various base substitution mutations induced either in control or in MeIQx-treated mice; the mechanisms involved in this alteration are not yet known.

The results from this study are consistent with the notion that the carcinogenicity of MeIQx is related to the accumulation of MeIQx-induced genetic mutations. Other studies have supported the general hypothesis that accumulation of mutations is pertinent to the development of cancer (27 , 28) . The high mutant frequency of the lacZ gene in MeIQx-treated mice paralleled the development of preneoplastic alterations and tumors in these mice. However, factors in addition to mutagenesis play a role in MeIQx-induced hepatocarcinogenesis. For example, in C57Bl/{lambda}lacZ mice on MeIQx diet for 40 weeks, lacZ mutant frequency was higher in female than in male mice, whereas tumor incidence was lower in females than in males. Sex differences in susceptibility to chemically induced hepatocarcinogenesis and sex differences in the incidence of hepatocarcinogenesis in humans (29 , 30) have been noted previously. Androgen levels in the male have been shown to contribute to a higher susceptibility of males to liver cancer (30) .

The use of the c-myc/{lambda}lacZ bitransgenic mouse strain for studies with MeIQx indicated that c-myc overexpression was associated with a dramatic acceleration of MeIQx-induced hepatocarcinogenesis. In fact, after 30 weeks on either MeIQx or control diet, only male c-myc mice fed MeIQx developed hepatocellular carcinoma. Neither c-myc overexpression alone nor MeIQx treatment alone induced hepatocellular carcinoma at this time point. These in vivo findings are consistent with a previous study showing that rodent embryo fibroblasts were more susceptible to in vitro transformation by chemical carcinogens when the cells expressed a high level of c-myc (31) .

The results from the current study in bitransgenic mice further suggest that the mechanism of the synergism between c-myc and MeIQx in hepatocarcinogenesis involves an enhancement of MeIQx-induced mutagenesis. In mice on MeIQx diet, mutant frequency was ~2-fold higher in the c-myc mice than in the control strain. Therefore, the relatively modest increase in mutations in the lacZ gene was associated with a 100% increase in the incidence of hepatocarcinogenesis. This finding raises the possibility that other types of genetic alterations, such as large deletion mutations or amplifications that are not detectable using the {lambda} phage-based lacZ transgene system (23) , also contribute to the enhancement of mutations and carcinogenesis. An additional explanation for this finding may be that, as a mutational reporter gene, lacZ provides an estimate of the mutations occurring in the genome, whereas mutations in specific critical genes that cooperate with c-myc are likely to lead to the enhancement of carcinogenesis.

Previous studies have shown that the rate of hepatic proliferation is significantly higher in the c-myc transgenic mice than in wild-type mice. For example, between 4 and 8 months of age, mitotic activity in mouse liver is 50–100-fold higher in male c-myc mice than in control mice not carrying the transgene (32) . This high rate of hepatic proliferation in c-myc mice is likely to facilitate the fixation of MeIQx-induced mutations from MeIQx-DNA adducts. In the multistep model of carcinogenesis, the higher frequency of MeIQx mutations in the genome would be expected to contribute to the accumulation of critical genetic alterations that give rise to neoplasia. A previous study showed that MeIQx-DNA adduct levels were statistically higher in c-myc/{lambda}lacZ mice than in C57Bl/{lambda}lacZ mice after 10 doses of MeIQx (12) . Although the trend for higher MeIQx-DNA adduct levels was observed with chronic feeding with MeIQx, the difference was not statistically significant. The results, therefore, suggest that the high rate of hepatic proliferation associated with c-myc overexpression rather than higher adduct levels in this strain is likely to be the major factor in determining higher mutant frequency in c-myc mice.

Recent studies have indicated that c-myc overexpression is associated with genomic instability (33 , 34) . For example, overexpression of c-myc in a variety of cell lines is followed by the amplification and rearrangement of the dihydrofolate reductase gene (34) . The results shown here indicate that c-myc overexpression is associated with an increase in the frequency of spontaneous base substitution mutations, as well as the frequency of carcinogen/mutagen-induced base substitution mutations. In both male and female mice on control diet for 40 weeks, lacZ mutant frequency was significantly higher in mice that harbored the c-myc gene than in the control strain. The findings raise the possibility that in addition to amplification and genomic rearrangements, the genomic instability associated with c-myc overexpression also includes point mutations. To our knowledge, this is the first study showing that c-myc increases the frequency of base substitution mutations in vivo. Whereas enhanced replication rate and disruption of the G1-S stage of the cell cycle with c-myc overexpression may partly account for the increase in mutagenesis (34) , the mechanisms by which c-myc overexpression enhances the frequency of spontaneous base substitution mutations still requires further study.

Studies in transgenic mouse models have indicated that c-myc cooperates with a variety of other genes to enhance carcinogenesis. For example, the combination of c-myc with an overexpressed TGF{alpha} gene or with mutated H-ras in bitransgenic mouse models causes a striking acceleration of hepatocarcinogenesis (32 , 35) . The results from this study also indicate that the synergistic effect of MeIQx and c-myc is likely to involve MeIQx-induced mutations in a critical gene or series of genes that cooperate with c-myc to accelerate malignant conversion. Additional studies are required to elucidate the genes mutated by MeIQx that cooperate with the overexpressed c-myc gene to facilitate hepatocellular carcinogenesis.


   ACKNOWLEDGMENTS
 
We thank Dr. Snorri S. Thorgeirsson (National Cancer Institute, Bethesda, MD) for providing the c-myc transgenic mice and for helpful advice and Dr. Jan Vijg (Harvard Medical School, Boston, MA) for providing the E. coli C strain.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Present address: United States Department of Agriculture, Grand Forks Human Nutrition Research Center, 2420 Second Avenue North, Grand Forks, ND 58202-9034. Back

2 To whom requests for reprints should be addressed, at Chemical Carcinogenesis Section, Laboratory of Experimental Carcinogenesis, National Cancer Institute, Building 37, Room 3C28, 37 Convent Drive, MSC 4255, Bethesda, MD 20892-4255. Back

3 The abbreviations used are: MeIQx, 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline; HCA, heterocyclic amine; P-gal, phenyl-ß-D-galactoside; AIN, American Institute of Nutrition. Back

Received 11/ 3/98. Accepted 4/ 5/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Layton D. W., Bogen K. T., Knize M. G., Hatch F. T., Johnson V. M., Felton J. S. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis (Lond.), 16: 39-52, 1995.[Abstract/Free Full Text]
  2. Ohgaki H., Hasegawa H., Suenaga M., Sato S., Takayama S., Sugimura T. Carcinogenicity in mice of a mutagenic compound 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) from cooked foods. Carcinogenesis (Lond.), 8: 665-668, 1987.[Abstract/Free Full Text]
  3. Davis C. D., Schut H. A. J., Adamson R. H., Thorgeirsson U. P., Thorgeirsson S. S., Snyderwine E. G. Mutagenic activation of IQ, PhIP and MeIQx by hepatic microsomes from rat, monkey and man: low mutagenic activation of MeIQx in cynomolgus monkeys in vitro reflects low DNA adduct levels in vivo. Carcinogenesis (Lond.), 14: 61-65, 1993.[Abstract/Free Full Text]
  4. Snyderwine E. G., Davis C. D., Nouso K., Roller P. P., Schut H. A. J. 32P-Postlabeling analysis of IQ, MeIQx and PhIP adducts formed in vitro in DNA and polynuceotides and found in vivo in hepatic DNA from IQ-, MeIQx and PhIP-treated monkeys. Carcinogenesis (Lond.), 14: 1389-1395, 1993.[Abstract/Free Full Text]
  5. Turesky R. J., Rossi S. C., Welti D. H., Lay J. O., Jr., Kadlubar F. F. Characterization of DNA adducts formed in vitro by reaction of N-hydroxy-2-amino-3-methylimidazo[4,5-f]quinoxaline at the C-8 and N2 atoms of guanine. Chem. Res. Toxicol., 5: 479-490, 1992.[Medline]
  6. Ochiai M., Nagaoka H., Wakabayashi K., Tanaka Y., Kim S-B., Tada A., Hukaya H., Sugimura T., Nagao M. Identification of N2-(deoxyguanosin-8-yl)-2-amino- 3: 8-dimethylimidazo[4,5-f]quinoxaline 3,5-diphosphate, a major DNA adduct, detected by nuclease P1 modification of the 32P-postlabeling method, in the liver of rats fed MeIQx. Carcinogenesis (Lond.), 14: 2165-2170, 1993.[Abstract/Free Full Text]
  7. Sugimura T. Overview of carcinogenic heterocyclic amines. Mutat. Res., 376: 211-219, 1997.[Medline]
  8. Felton J. S., Knize M. G. Occurrence, identification, and bacterial mutagenicity of heterocyclic amines in cooked food. Mutat. Res., 259: 205-217, 1991.[Medline]
  9. Watanabe M., Ohta T. Analysis of mutational specificity induced by heterocyclic amines in the lacZ gene of Escherichia coli. Carcinogenesis (Lond.), 14: 1149-1153, 1993.[Abstract/Free Full Text]
  10. Solomon M. S., Morgenthaler P. L., Turesky R. J., Essigmann J. M. Mutational, and DNA binding specificity of the carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. J. Biol. Chem., 271: 18368-18374, 1996.[Abstract/Free Full Text]
  11. Knasmuller S., Kienzi H., Huber W., Hermann R. S. Organ-specific distribution of genotoxic effects in mice exposed to cooked food mutagens. Mutagenesis, 7: 235-241, 1992.[Abstract/Free Full Text]
  12. Davis C. D., Dacquel E. J., Schut H. A. J., Thorgeirsson S. S., Snyderwine E. G. In vivo mutagenicity and DNA adduct levels of heterocyclic amines in Muta mice and c-myc/lacZ double transgenic mice. Mutat. Res., 356: 287-296, 1996.[Medline]
  13. Endo H., Schut H. A. J., Snyderwine E. G. Mutagenic specificity of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the supF shuttle vector system. Cancer Res., 54: 3745-3751, 1994.[Abstract/Free Full Text]
  14. Grisham J. W. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis (Lond.), 18: 59-81, 1997.[Abstract/Free Full Text]
  15. Facchini L. M., Penn L. Z. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J., 12: 633-651, 1998.[Abstract/Free Full Text]
  16. Packham G., Cleveland J. L. c-Myc and apoptosis. Biochim. Biophys. Acta, 1242: 11-28, 1995.[Medline]
  17. Sandgren E. P., Quaife C. J., Pinkert C. A., Palmiter C. D., Brinster R. L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene, 4: 715-724, 1989.[Medline]
  18. Murakami H., Sanderson N. D., Nagy P., Marino P. A., Merlino G., Thorgeirsson S. S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor {alpha} in hepatic oncogenesis. Cancer Res., 53: 1719-1723, 1993.[Abstract/Free Full Text]
  19. Leone G., DeGregori J., Sears R., Jakoi L., Nevins J. R. Myc, and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (Lond.), 387: 422-426, 1997.[Medline]
  20. Frith, C. H., Ward, J. M., and Turosov, V. S. Tumours of the liver. In: V. Turosov and U. Mohr (eds.), Pathology of Tumors in Laboratory Animals, vol. 2, Tumours of the Mouse, pp. 223–270. Lyon, France: IARC Scientific, 1994.
  21. Gupta R. C., Earley K., Sharma S. Use of human peripheral blood lymphocytes to measure DNA binding capacity of chemical carcinogens. Proc. Natl. Acad. Sci. USA, 85: 3513-3517, 1988.[Abstract/Free Full Text]
  22. Randerath E., Agarwal H. P., Weaver J. A., Bordelon C. B., Randerath K. 32P-postlabeling analysis of DNA adducts persisting for up to 42 weeks in skin, epidermis and dermis of mice treated topically with 7,12-dimethylbenz[{alpha}]anthracene. Carcinogenesis (Lond.), 6: 1117-1126, 1985.[Abstract/Free Full Text]
  23. Vijg J., Douglas G. R. Bacteriophage {lambda} and plasmid lacZ transgenic mice for studying mutations in vivo Pfeiffer G. P. eds. . Technologies for Detection of DNA Damage and Mutations, : 391-410, Plenum New York 1996.
  24. Dean S. W., Myhr B. Measurement of gene mutations in vivo using MutaTM Mouse and positive selection for LacZ phage. Mutagenesis, 9: 183-185, 1994.[Abstract/Free Full Text]
  25. Shapiro B. H., Agarwal A. K., Pampori N. A. Gender differences in drug metabolism regulated by growth hormone. Int. J. Biochem. Cell Biol., 27: 9-20, 1995.[Medline]
  26. Gossen J. A., de Leeuw W. J. F., Verwest A., Lohman P. H. M., Vijg J. High somatic mutation frequencies in a LacZ transgene integrated on the mouse X-chromosome. Mutat. Res., 250: 423-429, 1991.[Medline]
  27. Hemminki K. DNA adducts, mutations and cancer. Carcinogenesis (Lond.), 14: 2007-2012, 1993.[Abstract/Free Full Text]
  28. Loeb L. A. Many mutations in cancers. Cancer Surv., 28: 329-342, 1996.[Medline]
  29. Lotze M. T., Flickinger J. C., Carr B. I. Hepatobiliary neoplasms Ed. 4 Devita V. T., Jr. Hellman S. Bosenberg S. T., Jr. eds. . Cancer: Principle and Practice of Oncology, : 883-914, Lippincott Philadelphia 1993.
  30. Blanck A., Hansson T., Eriksson L. C., Gustafsson J. A. On mechanisms of sex differences in chemical carcinogenesis: effects of implantation of ectopic pituitary grafts on the early stages of liver carcinogenesis in the rat. Carcinogenesis (Lond.), 5: 1257-1262, 1984.[Abstract/Free Full Text]
  31. Hsiao W. L., Castro M., Giezentanner J., Fan H., Hanecak R. Acquisition of responsiveness to chemical carcinogens by rodent embryo fibroblasts expressing high levels of the c-myc proto-oncogene. Mol. Carcinogenesis, 5: 140-154, 1992.[Medline]
  32. Santoni-Rugiu E., Preisegger K. H., Kiss A., Audolfsson T., Shiota G., Schmidt E. V., Thorgeirsson S. S. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc. Natl. Acad. Sci. USA, 93: 9577-9582, 1996.[Abstract/Free Full Text]
  33. Chernova O. B., Chernov M. V., Ishizaka Y., Agarwal M. L., Stark G. R. MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol. Cell. Biol., 18: 536-545, 1998.[Abstract/Free Full Text]
  34. Mai S., Hanley-Hyde J., Fluri M. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene, 12: 277-288, 1996.[Medline]
  35. Leone G., DeGregori J., Sears R., Jakoi L., Nevins J. R. Myc, and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (Lond.), 387: 422-426, 1997.



This article has been cited by other articles:


Home page
 Toxicol SciHome page
M. Hoshi, K. Morimura, H. Wanibuchi, M. Wei, E. Okochi, T. Ushijima, K. Takaoka, and S. Fukushima
No-Observed Effect Levels for Carcinogenicity and for in vivo Mutagenicity of a Genotoxic Carcinogen
Toxicol. Sci., October 1, 2004; 81(2): 273 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Felix, A. Polack, W. Pretsch, S. H. Jackson, L. Feigenbaum, G.-W. Bornkamm, and S. Janz
Moderate Hypermutability of a Transgenic lacZ Reporter Gene in Myc-Dependent Inflammation-Induced Plasma Cell Tumors in Mice
Cancer Res., January 15, 2004; 64(2): 530 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. F. Calvisi, V. M. Factor, R. Loi, and S. S. Thorgeirsson
Activation of {beta}-Catenin during Hepatocarcinogenesis in Transgenic Mouse Models: Relationship to Phenotype and Tumor Grade
Cancer Res., March 1, 2001; 61(5): 2085 - 2091.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryu, D.-Y.
Right arrow Articles by Snyderwine, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryu, D.-Y.
Right arrow Articles by Snyderwine, E. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online